Clinical Trial Update: Evaluate the Safety of Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) in Healthy Females [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating the safety of a recombinant HPV-16/18 bivalent vaccine produced in yeast in healthy women.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infection

Drugs mentioned

• Recombinant Human Papillomavirus Bivalent (Types 16 and 18) Vaccine (Yeast) (HPV16/18 L1 virus-like particle vaccine)

Snippet

Sponsor: Shanghai Zerun Biotechnology Co.,Ltd | Conditions: Human Papillomavirus | Phase 1 | Status: UNKNOWN